Serum B-cell activating factor is not a potential biomarker for disease activity in chronic inflammatory demyelinating polyneuropathy

被引：1
作者：
Michael, Milou R. [1 ,5 ]
Wieske, Luuk [1 ,2 ]
Koel-Simmelink, Marleen J. [3 ]
van Schaik, Ivo N. [1 ,4 ]
Teunissen, Charlotte E. [3 ]
Eftimov, Filip [1 ]
机构：
[1] Univ Amsterdam, Dept Neurol, Amsterdam UMC, Amsterdam Neurosci, Amsterdam, Netherlands
[2] St Antonius Hosp, Dept Clin Neurophysiol, Nieuwegein, Netherlands
[3] Vrije Univ Amsterdam Med Ctr, Dept Clin Chem, Neurochem Lab, Amsterdam UMC,Amsterdam Neurosci, Amsterdam, Netherlands
[4] Sanquin, Amsterdam, Netherlands
[5] Amsterdam UMC, Locat AMC, Dept Expt Cardiol, H2-235,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
来源：
JOURNAL OF NEUROIMMUNOLOGY | 2023年 / 382卷
关键词：
B-cell activating factor; CIDP; Disease activity; Biomarker; NECROSIS-FACTOR FAMILY; BAFF;
D O I：
10.1016/j.jneuroim.2023.578169
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
B-cell activating factor (BAFF) is a crucial cytokine for differentiation and survival of B-cells and correlates to disease activity in some auto-immune diseases. To evaluate BAFF as a biomarker for disease activity in chronic inflammatory demyelinating polyneuropathy (CIDP), serum BAFF levels were measured at varying disease stages: patients starting treatment, patients starting treatment withdrawal, patients in remission and healthy controls. Serum BAFF levels were elevated in patients compared to healthy controls, but did not differ between patients starting treatment and patients in remission. Serum BAFF levels did not change with or predict treatment response or relapse. Serum BAFF is not a responsive biomarker reflecting disease activity in CIDP.
引用
收藏
页数：5
相关论文
共 20 条
  • [1] Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study
    Adrichem, M. E.
    Bus, S. R.
    Wieske, L.
    Mohammed, H.
    Verhamme, C.
    Hadden, R.
    van Schaik, I. N.
    Eftimov, F.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (03) : 506 - 513
  • [2] Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy
    Adrichem, Max E.
    Lucke, Ilse M.
    Vrancken, Alexander F. J. E.
    Goedee, H. Stephan
    Wieske, Luuk
    Dijkgraaf, Marcel G. W.
    Voermans, Nicol C.
    Notermans, Nicolette C.
    Faber, Catharina G.
    Visser, Leo H.
    Kuitwaard, Krista
    van Doorn, Pieter A.
    Merkies, Ingemar S. J.
    de Haan, Rob J.
    van Schaik, Ivo N.
    Eftimov, Filip
    [J]. BRAIN, 2022, 145 (05) : 1641 - 1652
  • [3] BAFF mediates survival of peripheral immature B lymphocytes
    Batten, M
    Groom, J
    Cachero, TG
    Qian, F
    Schneider, P
    Tschopp, J
    Browning, JL
    Mackay, F
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (10) : 1453 - 1465
  • [4] Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy - A new mechanism of action?
    Bick, Sandra
    Tschernatsch, Marlene
    Karg, Anne
    Fuehlhuber, Verena
    Trenczek, Tina E.
    Faltermeier, Kathrin
    Hackstein, Holger
    Kaps, Manfred
    Blaes, Franz
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2013, 256 (1-2) : 84 - 90
  • [5] Clinical outcome of CIDP one year after start of treatment: a prospective cohort study
    Bus, S. R. M.
    Broers, M. C.
    Lucke, I. M.
    Bunschoten, C.
    van Lieverloo, G. G. A.
    Adrichem, M. E.
    van Veen, R.
    Wieske, L.
    Lingsma, H. F.
    Goedee, H. S.
    van der Pol, W. L.
    van Schaik, I. N.
    Van Doorn, P. A.
    Jacobs, B. C.
    Eftimov, F.
    [J]. JOURNAL OF NEUROLOGY, 2022, 269 (02) : 945 - 955
  • [6] Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy
    Eftimov, Filip
    Winer, John B.
    Vermeulen, Marinus
    de Haan, Rob
    van Schaik, Ivo N.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (01):
  • [7] European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision
    Hadden, Robert D. M.
    Nobile-Orazio, Eduardo
    Sommer, Claudia L.
    Hahn, Angelika F.
    Illa, Isabel
    Morra, Enrica
    Pollard, John D.
    Lunn, Michael P. T.
    Bouche, Pierre
    Cornblath, David R.
    Evers, Eileen
    Koski, Carol Lee
    Legar, Jean-Marc
    van den Bergh, Peter
    van Doorn, Pieter A.
    van Schaik, Ivo N.
    [J]. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2010, 15 (03) : 185 - 195
  • [8] Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
    Hughes, Richard A. C.
    Mehndiratta, Man Mohan
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (01):
  • [9] Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies
    Krystufkova, O.
    Vallerskog, T.
    Helmers, S. Barbasso
    Mann, H.
    Putova, I.
    Belacek, J.
    Malmstrom, V.
    Trollmo, C.
    Vencovsky, J.
    Lundberg, I. E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (06) : 836 - 843
  • [10] BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator
    Moore, PA
    Belvedere, O
    Orr, A
    Pieri, K
    LaFleur, DW
    Feng, P
    Soppet, D
    Charters, M
    Gentz, R
    Parmelee, D
    Li, YL
    Galperina, O
    Giri, J
    Roschke, V
    Nardelli, B
    Carrell, J
    Sosnovtseva, S
    Greenfield, W
    Ruben, SM
    Olsen, HS
    Fikes, J
    Hilbert, DM
    [J]. SCIENCE, 1999, 285 (5425) : 260 - 263
12